{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:56:55Z","timestamp":1767175015306,"version":"build-2238731810"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) infection prevalence is particularly high in people who inject drugs (PWID), a population that faces many barriers to HCV testing and care. A better understanding of the determinants of access to HCV testing is needed to improve their engagement in the HCV care cascade. We used data from a cross-sectional survey of people who inject drugs, mainly opioids, to identify factors associated with recent HCV testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Self-reported data on HCV antibody testing were analyzed for 550 of the 557 PWID enrolled in PrebupIV, a French cross-sectional community-based survey which assessed PWID acceptability of injectable buprenorphine as a treatment. Factors associated with recent (i.e., in the previous six months) HCV antibody testing were identified performing multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the study sample, 79% were men and 31% reported recent HCV antibody testing. Multivariable analysis found that PWID who did not disclose their injection practices to anyone (aOR [95% CI] 0.31 [0.12,0.82],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018), older PWID (aOR [95% CI] 0.97 [0.95,1.00],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030) and employed respondents (aOR [95% CI] 0.58 [0.37,0.92],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019) were all less likely to report recent HCV testing. No association was found between opioid agonist therapy and HCV testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that non-disclosure of injection practices, employment and age were all barriers to HCV antibody testing. Preventing stigma around injection practices, developing the HCV testing offer in primary care and addiction care services, and training healthcare providers in HCV care management could improve HCV testing and therefore, the HCV care cascade in PWID.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-023-00841-7","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T11:01:47Z","timestamp":1690628507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study"],"prefix":"10.1186","volume":"20","author":[{"given":"Ilhame","family":"Anwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Donadille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia","family":"Protopopescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Michels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Herin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad\u00e9la\u00efde","family":"Pladys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00e8le","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"issue":"12","key":"841_CR1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","volume":"16","author":"L Degenhardt","year":"2016","unstructured":"Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(12):1385\u201398.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"841_CR2","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"841_CR3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.respe.2015.10.003","volume":"64","author":"L Weill-Barillet","year":"2016","unstructured":"Weill-Barillet L, Pillonel J, Semaille C, L\u00e9on L, Le Strat Y, Pascal X, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Rev d\u2019\u00c9pid\u00e9miol Sant\u00e9 Publique. 2016;64(4):301\u201312.","journal-title":"Rev d\u2019\u00c9pid\u00e9miol Sant\u00e9 Publique"},{"issue":"1","key":"841_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/add.14393","volume":"114","author":"J Grebely","year":"2019","unstructured":"Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction (Abingdon, England). 2019;114(1):150\u201366.","journal-title":"Addiction (Abingdon, England)"},{"key":"841_CR5","first-page":"224","volume":"13\u201314","author":"C Pioche","year":"2016","unstructured":"Pioche C. Estimation de la pr\u00e9valence de l\u2019h\u00e9patite C en population g\u00e9n\u00e9rale, France m\u00e9tropolitaine, 2011. Bull Epid\u00e9miol Hebd. 2016;13\u201314:224\u20139.","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"841_CR6","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. 2016. p. 52. http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf?ua=1."},{"key":"841_CR7","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9. La strat\u00e9gie nationale de sant\u00e9 2018\u20132022; 2017. p. 104."},{"issue":"1","key":"841_CR8","first-page":"20","volume":"39","author":"E Day","year":"2019","unstructured":"Day E, Hellard M, Treloar C, Bruneau J, Martin NK, \u00d8vrehus A, et al. Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int Off J Int Assoc Study Liver. 2019;39(1):20\u201330.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"841_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drugpo.2017.05.019","volume":"47","author":"J Grebely","year":"2017","unstructured":"Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, et al. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51\u201360.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"841_CR10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3325\/cmj.2016.57.442","volume":"57","author":"JV Lazarus","year":"2016","unstructured":"Lazarus JV, Sperle I, Spina A, Rockstroh JK. Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe. Croat Med J. 2016;57(5):442\u201356.","journal-title":"Croat Med J"},{"key":"841_CR11","first-page":"4","volume":"142","author":"A Cadet-Ta\u00efrou","year":"2020","unstructured":"Cadet-Ta\u00efrou A, Janssen \u00c9, Guilbaud F. Profils et pratiques des usagers re\u00e7us en CAARUD en 2019. Tendances. 2020;142:4.","journal-title":"Tendances"},{"issue":"1","key":"841_CR12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41124-018-0033-8","volume":"3","author":"JM Delile","year":"2018","unstructured":"Delile JM, de Ledinghen V, Jauffret-Roustide M, Roux P, Reiller B, Foucher J, et al. Hepatitis C virus prevention and care for drug injectors: the French approach. Hepatol Med Policy. 2018;3(1):7.","journal-title":"Hepatol Med Policy"},{"issue":"4","key":"841_CR13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.28227","volume":"63","author":"A Cousien","year":"2016","unstructured":"Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology (Baltimore, MD). 2016;63(4):1090\u2013101.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"841_CR14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41124-016-0011-y","volume":"1","author":"JF Dillon","year":"2016","unstructured":"Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1:2.","journal-title":"Hepatol Med Policy"},{"key":"841_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7517-11-1","volume":"11","author":"JA Barocas","year":"2014","unstructured":"Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014;11:1.","journal-title":"Harm Reduct J"},{"issue":"2","key":"841_CR16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.idh.2018.10.006","volume":"24","author":"C Wright","year":"2019","unstructured":"Wright C, Cogger S, Hsieh K, Goutzamanis S, Hellard M, Higgs P. \u201cI\u2019m obviously not dying so it\u2019s not something I need to sort out today\u201d: considering hepatitis C treatment in the era of direct acting antivirals. Infect Dis Health. 2019;24(2):58\u201366.","journal-title":"Infect Dis Health"},{"key":"841_CR17","doi-asserted-by":"crossref","first-page":"103019","DOI":"10.1016\/j.drugpo.2020.103019","volume":"88","author":"KM Ward","year":"2021","unstructured":"Ward KM, McCormick SD, Sulkowski M, Latkin C, Chander G, Falade-Nwulia O. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. Int J Drug Policy. 2021;88:103019.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"841_CR18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/apc.2010.0142","volume":"24","author":"D Swan","year":"2010","unstructured":"Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDs. 2010;24(12):753\u201362.","journal-title":"AIDS Patient Care STDs"},{"key":"841_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7517-10-7","volume":"10","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10:7.","journal-title":"Harm Reduct J"},{"key":"841_CR20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"190","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. \u2018Hep C\u2019s like the common cold\u2019: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"841_CR21","doi-asserted-by":"crossref","first-page":"e0207226","DOI":"10.1371\/journal.pone.0207226","volume":"13","author":"A Madden","year":"2018","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS ONE. 2018;13(11):e0207226.","journal-title":"PLoS ONE"},{"issue":"9","key":"841_CR22","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jvh.13119","volume":"26","author":"AH Litwin","year":"2019","unstructured":"Litwin AH, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE Study. J Viral Hepat. 2019;26(9):1094\u2013104.","journal-title":"J Viral Hepat"},{"key":"841_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2019.07.016","volume":"72","author":"J Grebely","year":"2019","unstructured":"Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C. Elimination of hepatitis C virus infection among people who use drugs: ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy. 2019;72:1\u201310.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"841_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12954-020-00439-3","volume":"17","author":"M Maticic","year":"2020","unstructured":"Maticic M, Pirnat Z, Leicht A, Zimmermann R, Windelinck T, Jauffret-Roustide M, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J. 2020;17(1):89.","journal-title":"Harm Reduct J"},{"key":"841_CR25","doi-asserted-by":"crossref","unstructured":"Pol S, Fouad F, Lemaitre M, Rodriguez I, Lada O, Rabiega P, et al. Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015\u20132019) of data from French administrative healthcare databases (SNDS). Lancet Reg Health Eur. 2022. https:\/\/www.thelancet.com\/journals\/lanepe\/article\/PIIS2666-7762(21)00267-2\/fulltext.","DOI":"10.1016\/j.lanepe.2021.100281"},{"key":"841_CR26","first-page":"40","volume":"3\u20134","author":"C Goujard","year":"2022","unstructured":"Goujard C, Ayachi L, Arti\u00e8res P, Celse M, Fischer H, Musso S, et al. Pr\u00e9vention, d\u00e9pistage et traitement de l\u2019h\u00e9patite C chez les personnes d\u00e9tenues en France. Bull Epid\u00e9miol Hebd. 2022;3\u20134:40\u20137.","journal-title":"Bull Epid\u00e9miol Hebd"},{"issue":"1","key":"841_CR27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13011-017-0131-4","volume":"12","author":"P Roux","year":"2017","unstructured":"Roux P, Rojas Castro D, Ndiaye K, Briand Madrid L, Laporte V, Mora M, et al. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. Subst Abuse Treat Prev Policy. 2017;12(1):46.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"841_CR28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, Drainoni ML, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"841_CR29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jvh.12513","volume":"23","author":"M Harris","year":"2016","unstructured":"Harris M, Ward E, Gore C. Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom. J Viral Hepat. 2016;23(6):479\u201386.","journal-title":"J Viral Hepat"},{"issue":"1","key":"841_CR30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u2018They look at us like junkies\u2019: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.","journal-title":"Harm Reduct J"},{"key":"841_CR31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1747-597X-8-35","volume":"8","author":"K Lang","year":"2013","unstructured":"Lang K, Nei J, Wright J, Dell C, Berenbaum S, El-Aneed A. Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers. Subst Abuse Treat Prev Policy. 2013;8:35.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"841_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drugpo.2018.10.012","volume":"63","author":"J Grebely","year":"2019","unstructured":"Grebely J, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, et al. Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: the C-SCOPE study. Int J Drug Policy. 2019;63:29\u201338.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"841_CR33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.drugalcdep.2013.03.021","volume":"132","author":"D Horyniak","year":"2013","unstructured":"Horyniak D, Dietze P, Degenhardt L, Higgs P, McIlwraith F, Alati R, et al. The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. Drug Alcohol Depend. 2013;132(3):541\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"841_CR34","unstructured":"Dhumeaux D. Prise en charge th\u00e9rapeutique et suivi de l\u2019ensemble des personnes infect\u00e9es par le virus de l\u2019h\u00e9patite C -Rapport de recommandations 2016 [Internet]. Paris: Sous l\u2019\u00e9gide de l\u2019ANRS et du CNS et avec le concours de l\u2019AFEF; 2016 [cited 2021 Jul 21] p. 106. (La Documentation fran\u00e7aise). http:\/\/www.ladocumentationfrancaise.fr\/rapportspublics\/164000667\/index.shtml."},{"issue":"3","key":"841_CR35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2468-1253(22)00346-6","volume":"8","author":"A Trickey","year":"2023","unstructured":"Trickey A, Fajardo E, Alemu D, Artenie AA, Easterbrook P. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(3):253\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"841_CR36","first-page":"1","volume":"00","author":"M Debette-Gratien","year":"2023","unstructured":"Debette-Gratien M, Fran\u00e7ois S, Chevalier C, Alain S, Carrier P, Rigaud C, et al. Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days. J Viral Hepat. 2023;00:1\u20137.","journal-title":"J Viral Hepat"},{"key":"841_CR37","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jvh.12919","volume":"10","author":"A Cousien","year":"2018","unstructured":"Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, et al. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: the case of France. J Viral Hepat. 2018;10:1197.","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"841_CR38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/hiv.12589","volume":"19","author":"O Anagnostou","year":"2018","unstructured":"Anagnostou O, Fotiou A, Kanavou E, Antaraki A, Terzidou M, Richardson C, et al. Factors associated with HCV test uptake in heroin users entering substitution treatment in Greece. HIV Med. 2018;19(Suppl 1):34\u20139.","journal-title":"HIV Med"},{"key":"841_CR39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.drugpo.2017.07.008","volume":"47","author":"K Butler","year":"2017","unstructured":"Butler K, Day C, Sutherland R, van Buskirk J, Breen C, Burns L, et al. Hepatitis C testing in general practice settings: a cross-sectional study of people who inject drugs in Australia. Int J Drug Policy. 2017;47:102\u20136.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"841_CR40","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1093\/cid\/ciaa612","volume":"73","author":"J Grebely","year":"2021","unstructured":"Grebely J, Tran L, Degenhardt L, Dowell-Day A, Santo T, Larney S, et al. Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;73(1):e107\u201318.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"12","key":"841_CR41","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/liv.14208","volume":"39","author":"F Marcellin","year":"2019","unstructured":"Marcellin F, Roux P, Lazarus JV, Rolland B, Carrieri P. France removes hepatitis C treatment prescriber restrictions\u2014but what is the impact of the delay for key populations? Liver Int. 2019;39(12):2418\u20139.","journal-title":"Liver Int"},{"key":"841_CR42","doi-asserted-by":"crossref","first-page":"109050","DOI":"10.1016\/j.drugalcdep.2021.109050","volume":"228","author":"D Gibbs","year":"2021","unstructured":"Gibbs D, Price O, Grebely J, Larney S, Sutherland R, Read P, et al. Hepatitis C virus cascade of care among people who inject drugs in Australia: factors associated with testing and treatment in a universal healthcare system. Drug Alcohol Depend. 2021;228:109050.","journal-title":"Drug Alcohol Depend"},{"key":"841_CR43","unstructured":"HAS. H\u00e9patite C\u202f: prise en charge simplifi\u00e9e chez l\u2019adulte [Internet]. Haute Autorit\u00e9 de Sant\u00e9. 2019. p. 4. https:\/\/www.has-sante.fr\/jcms\/c_2911891\/fr\/hepatite-c-prise-en-charge-simplifiee-chez-l-adulte#voirAussi."},{"key":"841_CR44","unstructured":"Di Nino F. Impact du travail en r\u00e9seau de la m\u00e9decine de ville. R\u00e9duction Risques Infect Chez Usagers Drogue INSERM \u00ab\u202fExpert Collect\u202f\u00bb. 2010;489\u201392."},{"key":"841_CR45","first-page":"400","volume":"37","author":"F Di Nino","year":"2009","unstructured":"Di Nino F, Imbs JL, Melenotte GH, R\u00e9seau RMS, Doffoel M. D\u00e9pistage et traitement des h\u00e9patites C par le r\u00e9seau des microstructures m\u00e9dicales chez les usagers de drogues en Alsace, France, 2006\u20132007. Bull \u00c9pid\u00e9miol Hebd BEH. 2009;37:400\u20134.","journal-title":"Bull \u00c9pid\u00e9miol Hebd BEH"},{"issue":"3","key":"841_CR46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0376-8716(98)00028-3","volume":"51","author":"S Darke","year":"1998","unstructured":"Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253\u201363 (discussion 267\u2013268).","journal-title":"Drug Alcohol Depend"},{"key":"841_CR47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugpo.2019.01.012","volume":"66","author":"E Day","year":"2019","unstructured":"Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, et al. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. Int J Drug Policy. 2019;66:87\u201393.","journal-title":"Int J Drug Policy"}],"updated-by":[{"DOI":"10.1186\/s12954-023-00848-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000}}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00841-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00841-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00841-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T17:20:25Z","timestamp":1700328025000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00841-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00841-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12954-023-00848-0","URL":"https:\/\/doi.org\/10.1186\/s12954-023-00848-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey was authorized by the national French Data Protection Authority (<i>Commission Nationale de l'Informatique et des Libert\u00e9s<\/i> (CNIL)) (approval number 1812588v0\u201305\/12\/2014). The survey protocol was designed in accordance with the 1964 Helsinki Declaration, and all participants provided informed consent prior to their inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}